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& Abstract
Background: Opioids provide effective relief from moder-
ate-to-severe pain and should be prescribed as part of a
multifaceted approach to pain management when other
treatments have failed. Fixed-dose oxycodone/naloxone
prolonged-release tablets (OXN PR) were designed to address
the opioid class effect of opioid-induced constipation (OIC)
by combining the analgesic efficacy of oxycodone with the
opioid receptor antagonist, naloxone, which has negligible
systemic availability when administered orally. This
Address correspondence and reprint requests to: Sara L. Dickerson, MSc, Mundipharma International Ltd, 194 Cambridge Science Park, Milton Road,
Cambridge CB4 0AB, U.K. E-mail: Sara.Dickerson@mundipharma.com.
Conflicts of interest: B.C.C. has received consultancy fees/honoraria from Mundipharma International Ltd, Allergan France and Kyowa Kirin France.
S.L.D. is an employee of Mundipharma International Ltd. W.L. is an editor at www.paineurope.com. S.A.M-L. has received consultancy fees from
Mundipharma International Ltd, Mundipharma Research GmbH & Co. KG, Develco Pharma, and AstraZeneca. B.J.M. has received speaker/consultancy fees
from Astellas, Boehringer-Ingelheim, Gr€unenthal, Janssen-Cilag, Mundipharma International Ltd, Mundipharma Research GmbH & Co. KG, Pfizer Inc., and
Zambon. T.O’B. has received honoraria and consultancy fees from Archimedes, AstraZeneca, Gr€unenthal, Janssen-Cilag, Mundipharma, Mundipharma-
associated companies, and Teva. R.V. has no conflicts of interest to disclose with companies linked to the content of this manuscript. R.V. has academic
relationships for intellectual scientific activities (including participation as a speaker and in scientific advisory boards) with Gr€unenthal, Italfarmaco,
Molteni, and Norgine.
Submitted: June 25, 2017; Revised September 14, 2017;
Revision accepted: September 21, 2017
DOI. 10.1111/papr.12646
© 2017 The Authors. Pain Practice published by Wiley Periodicals, Inc. on behalf of World Institute of Pain, This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited,
the use is non-commercial and no modifications or adaptations are made., 1530-7085/16/$15.00
Pain Practice, Volume , Issue , 2017 –
formulation has abuse-deterrent properties, since systemic
exposure to naloxone by parenteral administration would
antagonize the euphoric effects of oxycodone.
Methods: A literature search was conducted to assess the
evidence base for OXN PR to treat moderate-to-severe pain
and its impact on bowel function, based on published clinical
trials and observational studies.
Results: Extensive data demonstrate that OXN PR provides
effective analgesia and clinically relevant improvements in
bowel function in patients with OIC and moderate-to-severe
cancer-related pain and noncancer pain types such as low
back pain, neuropathic pain, and musculoskeletal pain. OXN
PR has also been found to improve bowel function in patients
with OIC refractory to multiple types of laxatives, and
improve Parkinson’s disease–related pain. No unanticipated
safety concerns have been reported in elderly patients.
Conclusions: Evidence from clinical trials and observational
studies confirms that for selectedpatientsOXNPR significantly
improves moderate-to-severe chronic pain and provides relief
from OIC. Treatment should be tailored to individual patients
to establish the lowest effective dose. An absence of analgesic
ceiling effectwas seen across the clinically relevant dose range
investigated (≤ 160/80 mg/day). &
Key Words: narcotic antagonists, opioid analgesics, pain,
opioid-related disorders
INTRODUCTION
Moderate-to-severe chronic pain is highly debilitating
and has an estimated prevalence of approximately
20%.1,2 In cancer patients, moderate-to-severe chronic
pain is particularly common, affecting over half of
individuals with advanced disease despite increased
attention on pain assessment and management.3 Anal-
gesic drugs have a central role in managing chronic pain
and are used as part of a multifaceted approach that
integrates a variety of strategies, including interven-
tional, psychological, physical, and complementary
approaches, which together aim to improve pain treat-
ment and enable rehabilitation.4
Selection of analgesic drugs should be governed by a
comprehensive assessment of each patient in order to
determine the pathophysiology of his or her pain,
remembering that multiple pain types may be present.
Evidence-based treatment guidelines for moderate-to-
severe chronic pain indicate that opioid therapy can be
very effective for carefully selected patients inwhompain
has not responded to other measures.5–7 However, use of
opioid analgesics should be balanced against adverse
effects that occur in most patients, as well as the risks for
abuse and addiction.5,7 Recent guidance from the Euro-
pean Pain Federation advocates that patients be fully
informed about the potential risks and benefits of opioid
therapy, and an individualized approach to patient care is
undertaken.7 This includes a therapeutic trial to establish
whether or not opioid analgesia should be continued and
regular clinical reviews to assess efficacy, compliance,
physical, and psychological well-being of patients,
adverse effects, and possible addiction/abuse or misuse.7
Opioid-induced bowel dysfunction (OIBD) is a com-
mon class effect of opioid analgesics. OIBD arises when
exogenous opioids bind to enteric l-opioid receptors
present throughout the gastrointestinal tract, decreasing
peristalsis and gastric emptying while elevating resting
muscle tone and increasing nonpropulsive motility.8 Up
to 80% of patients receiving opioid analgesics report
symptoms of OIBD, such as dry mouth, nausea, acid
reflux, decreased appetite, abdominal pain, bloating,
and constipation, with opioid-induced constipation
(OIC) and straining to pass a bowel movement consid-
ered the most bothersome adverse effect.9 Treatment
guidelines recommend that laxatives be routinely pre-
scribed to patients receiving opioid analgesia, but
acknowledge that evidence supporting the prophylactic
use of laxatives in this setting is lacking.7,10–13 Several
studies indicate that laxatives fail to address symptoms
of OIC for some patients and can also be associated with
troublesome adverse effects that can impact normal
daily activities, such as bloating, flatulence, and sudden
urge to defecate.9,14–16 A recent pilot study in which
patients were prescribed laxatives at the onset of opioid
therapy concluded this paradigm was unlikely to
prevent or treat OIC.17 Laxatives can be ineffective for
OIC due to the unique etiology of this condition
compared with other types of constipation. Laxatives
aid defecation via localized effects in the colon, while
OIC arises from altered motility, secretion, and fluid
resorption throughout the gastrointestinal tract follow-
ing stimulation of enteric l-opioid receptors.18,19
OIC does not appear to be correlated with the
strength or dose of opioid, and management of OIC is
further complicated by the fact that clinical measures of
constipation, such as number of bowel movements per
week, often do not correlate with patient experi-
ence.15,20 Indeed, patient-assessment scales of constipa-
tion are advocated to ensure identification of affected
individuals. Assessment tools validated in OIC include
the Constipation Assessment Scale (CAS), Patient
Assessment of Constipation Symptoms (PAC-SYM),
Bowel Function Diary, and Bowel Function Index
(BFI).21–25 The CAS and PAC-SYM are well established,
patient-completed tools that are considered to have
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utility in clinical trials rather than in clinical practice,
largely due to comprehension difficulties and the time
taken to complete, respectively.20 Further validation of
the self-reported Bowel Function Diary is recommended
along with adjustments to account for redundancies
among items.10,20 The BFI is a brief, physician-
administered tool to assess patients’ perception of
OIC. It has been validated in several studies, with scores
lower than 28.8 considered normal, based on noncon-
stipated patients with chronic pain.20–22,26 BFI is
recommended by the American Academy of Pain
Medicine as the most appropriate tool for assessing
OIC, stating that patients receiving opioid analgesics
who have a BFI score of ≥ 30 should be considered for
specific treatment to improve bowel function if they fail
to respond to dietary and over-the-counter treatments.10
Oxycodone/naloxone prolonged-release tablets
(OXN PR) are approved in Europe to treat severe pain
that can only be adequately managed with opioids
(starting daily dose 10/5 mg twice daily [bid] oxy-
codone/naloxone, maximum daily dose 160/80 mg) and
severe idiopathic restless legs syndrome (starting daily
dose 5/2.5 mg bid, maximum daily dose 60/30 mg).27
OXN PR was designed to address OIBD by combining
the analgesic efficacy of oxycodone (OXY) with selec-
tive blockade of enteric l-opioid receptors by naloxone.
While intravenous naloxone rapidly crosses the blood–
brain barrier, the activity of oral naloxone (investigated
dose range 5 to 120 mg) is principally confined to the
gastrointestinal tract (bioavailability ≤ 2%) due to
extensive first-pass hepatic metabolism.28 As a result,
oral naloxone can prevent or reverse OIC but does not
reverse analgesia provided by OXY.29,30 The fixed-dose
combination of OXN PR is bioequivalent to OXY PR
and naloxone PR given separately.31 There is also
limited clinical evidence indicating that ultralow doses
of naloxone administered with morphine, buprenor-
phine, or tramadol may have an opioid-sparing effect,
enhance analgesia, and/or reduce the severity of some
OIBD symptoms.32–39
This review aims to assess the evidence base for OXN
PR as a treatment for moderate-to-severe pain and the
impact of this treatment on bowel function, based on
published literature.
LITERATURE SEARCH
A search of PubMed was conducted (up to February 2,
2017) to identify clinical trials and observational
studies investigating OXN PR for cancer-related pain
and across nonmalignant pain settings. The search
terms “random*”, “observation*”, and “pain” were
each combined with “OXN PR” and “oxycodone
AND naloxone”. In total, 45 publications capturing
38 clinical trials and observational studies were
identified that investigated OXN PR across a wide
range of settings. Three additional congress abstracts
detailing clinical studies on the analgesic use of OXN
PR (not identified in the PubMed searches) were
identified from a Mundipharma/Napp Pharmaceuticals
database. This literature analysis also included 4 cost-
effectiveness studies of OXN PR identified in the
PubMed searches.
OXN PR for Chronic, Moderate-to-Severe Cancer-
Related Pain
Evidence-based guidelines advocate the use of opioid
analgesics to treat moderate-to-severe cancer-related
pain, with oral morphine, OXY, or hydromorphone as
the first choice treatment in this setting.6 OXN PR has
been investigated in a range of studies in patients with
moderate-to-severe cancer-related pain (Table 1). These
include 2 randomized controlled trials (RCTs) of dou-
ble-blind treatment with OXN PR vs. OXY PR. The first
reported RCT was a phase II study investigating OXN
PR (≤ 120/60 mg/day) for 4 weeks, followed by an
optional 24-week extension phase of open-label OXN
PR.40,41 OXN PR was associated with analgesic efficacy
and safety that were comparable to those of OXY PR
and provided clinically relevant improvements in bowel
function measures that were maintained with long-term
open-label OXN PR.40,41 The second RCT was a recent
5-week phase III study with a 24-week open-label
extension phase and included patients with OIC who
required high-dose opioid to treat cancer-related or
noncancer pain. OXN PR at daily doses of up to 160/
80 mg provided effective analgesia and improved bowel
function compared with OXY PR.42,43 Subgroup anal-
ysis indicated greater pain relief in individuals receiving
140 to 160 mg/day compared with 100 to 120 mg/day,
indicating absence of an analgesic ceiling effect at these
doses. Outcomes in the subgroup of patients with
cancer-related pain were comparable to those in the
total population, and no additional safety concerns were
identified.42,43
The findings from both RCTs are supported by open-
label studies, including a 60-day observational study of
119 patients (78% with OIC [mean baseline BFI score
> 29]) who required OXN PR at daily doses of ≥ 80/
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40 mg to manage their cancer-related pain.44 Compared
with baseline (93% had received World Health Orga-
nization [WHO] stage III opioids) OXN PR reduced
pain intensity, the impact of pain on quality of life
(QoL), and the number of breakthrough pain episodes.
Furthermore, by day 60, mean (SD) BFI scores (33.9
[21.8]) were near to normal values and substantially
lower than reported at baseline (58.4 [29.9]) despite
reduced use of laxatives/enemas.44 A retrospective,
propensity-matched study reported OXN PR to be
associated with analgesic efficacy comparable to that of
OXY PR and to provide significant improvements in BFI
scores.45 In a 4-week observational study of patients with
non–small cell lung cancer and neuropathic pain, 82%
responded to treatment (≥ 30%reduction in average pain
intensity) with OXN PR plus pregabalin, with improved
BFI and other health-related patient-reported outcomes
(PROs).46 A 14-day observational study of OXN PR in
Table 1. Summary of Clinical Trials, Observational Studies, and Case Studies Investigating OXN PR for Cancer-Related
Pain
Reference Study Overview Key Outcomes
Ahmedzai
et al.40, 41
Double-blind 4-week RCT of OXN
PR (≤ 120/60 mg/day) vs.
OXY PR (n = 185) followed by 24-week
open-label extension
phase (OXN PR, n = 128) in patients with
moderate-to-severe cancer-related pain (OXN2001)
 OXN PR vs. OXY PR improved BFI scores (P < 0.01), constipation-related
QoL assessments (EORTC QLQ-C30 subscore) and reduced laxative
intake by 20% (P = 0.17)
 OXN PR provided noninferior analgesia (BPI-SF) to OXY PR (P < 0.01)
 Comparable safety profile with OXN PR and OXY PR
 Long-term OXN PR provided sustained analgesia and bowel function
 Patients who received OXY PR during the RCT experienced improved
bowel function with open-label OXN PR
Amato
et al.44
Observational 60-day study of patients with
moderate-to-severe cancer-related pain despite
analgesic treatment and/or opioid-related AEs
(nausea, vomiting, or OIC) switched to OXN
PR ≥ 80 mg/day to manage their pain; n = 119
 OXN PR reduced pain (≥ 30% decrease in average pain intensity,
P = 0.0001), impact of pain on QoL (BPI-SF, P < 0.0001), and the mean
number of daily breakthrough pain episodes (P < 0.01) from baseline
(the proportion of patients reporting ≥ 1 breakthrough pain episode
in the past 24 hours was not significantly different from baseline)
 BFI scores improved from baseline (P < 0.001) and the proportion of
patients receiving laxatives and/or enemas declined (P < 0.001)
 Number of patients reporting AEs decreased from baseline (P < 0.0001)
Clemens
et al.47
Open-label, 14-day, single-center study of
OXN PR (titrated to adequate pain control)
in patients with OIC; n = 26
 OXN PR was associated with significant improvements in BFI, stool
consistency, spontaneous bowel movements, and Patient Global
Impression (all P < 0.0001)
 OXN PR provided effective analgesia for most (21/26) patients
Cuomo
et al.48
Retrospective, single-center 28-day observational
study of OXN PR (starting dose ≤ 10/5 mg bid).
Patients had moderate-to-severe pain despite
analgesic therapy or AEs requiring treatment
modification; n = 206
 Switching to OXN PR provided significantly improved pain relief
(P < 0.0001) without impairing bowel function (no clinically
significant improvement in BFI)
 No severe/unanticipated AEs were reported
De Santis
et al.46
Open-label, 4-week observational study of
OXN PR ≤ 80/40 mg/day) + pregabalin for
patients with NSCLC and severe pain with
a neuropathic component; n = 56
 OXN PR + pregabalin improved average pain intensity (P < 0.0001),
BPI-SF (P = 0.0002), and episodes/intensity of breakthrough pain
(P ≤ 0.005)
 Improvements in BFI (P < 0.0001) and other health-related PROs
(HADS, P ≤ 0.0006; SDS, P < 0.001) were also reported; 66% were
satisfied/very satisfied with the therapy
 Treatment was well tolerated
Dupoiron
et al.42,43
Double-blind 5-week RCT of OXN PR (≤ 160/80 mg/day)
vs. OXY PR (n = 243) followed by 24-week open-label
extension phase (OXN PR ≤ 180/90 mg/day, n = 195) in
patients with OIC and cancer-related or noncancer pain
requiring doses ≥ 80 mg/day to manage their pain (OXN3506)
 Overall population: OXN PR vs. OXY PR was associated with
noninferior analgesia (P < 0.001), greater reductions in BFI, less
laxative use (P = 0.006), and more CSBM
 Analgesia and bowel function were maintained long-term with
open-label OXN PR
 Comparable observations were reported in the subgroup of patients
with cancer-related pain (n = 46)
Lazzari
et al.45
Single-center, retrospective, observational, propensity
matched study of OXN PR vs. OXY PR
(5 to 20 mg/day starting dose); n = 146
 OXN PR and OXY PR provided similar analgesic efficacy
 BFI improved from baseline with OXN PR but worsened with
OXY PR (P < 0.0001)
 ADRs were less frequent with OXN PR vs. OXY PR
(8 vs. 29%, P = 0.002)
ADR, adverse drug reaction; AE, adverse event; BFI, bowel function index; bid, twice daily; BPI-SF, Brief Pain Inventory-Short Form; CSBM, complete, spontaneous bowel movement;
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30; HADS, Hospital Anxiety and Depression Scale; NSCLC, non–small cell
lung cancer; OIC, opioid-induced constipation; OXN PR, prolonged-release oxycodone/naloxone; OXY PR, prolonged-release oxycodone; QoL, quality of life; PRO, patient-reported
outcome; RCT, randomized, controlled trial; SDS, Symptom Distress Scale.
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cancer patients with OIC also reported significant
improvements in pain intensity, BFI, and stool consis-
tency.47 A further observational study of cancer patients
treated in an outpatient setting also reported significant
improvements in pain scores with OXN PR, although no
clinically significant change in BFI scores or laxative
intake was observed compared with prior analgesic
therapy (19% and 49% had received step II and step III
WHO opioids, respectively).48
OXN PR for Moderate-to-Severe Noncancer Pain
Treatment guidelines recommend opioid therapy can be
considered for chronic noncancer pain that has not
responded to other treatments and is having an adverse
impact on patients’ QoL or daily functioning, and the
therapeutic benefits are considered to outweigh poten-
tial harm.5,7 Opioid analgesia should be initiated on a
trial basis, with titration to the lowest effective dose, and
therapy individualized according to each patient’s health
status, therapeutic goals, previous exposure to opioids,
and predicted harms.5,7 Our literature search identified a
broad range of evidence for the role of OXN PR in
moderate-to-severe noncancer pain settings, including
low back pain, musculoskeletal pain, neuropathic pain,
Parkinson’s disease–related pain, and postoperative
pain. These studies encompassed a variety of study
designs, from phase 3 RCTs and large-scale, observa-
tional “real-world” studies to smaller pilot studies
(Tables 2–6).
Table 2. Summary of Clinical Trials, Observational Studies, and Case Studies Investigating OXN PR for Low Back Pain
Reference Study Overview Key Outcomes
Baron
et al.67,68
12-week RCT of tapentadol vs. OXN PR
(starting dose 10/5 mg bid)
in opioid-na€ıve patients with severe,
chronic low back pain
(neuropathic component); n = 258
 Tapentadol had noninferior analgesic efficacy and PAC-SYM vs.
OXN PR (both, P < 0.001, primary endpoints)
 Greater improvements in neuropathic pain-related symptoms
(P ≤ 0.005), global health status (P = 0.005), and HRQoL (P ≤ 0.017)
with tarpentadol vs. OXN PR
 Tapentadol had better gastrointestinal tolerability
(constipation and vomiting) vs. OXN PR (P ≤ 0.045)
Cloutier
et al.61
Canadian regulatory cross-over, 4-week RCT of OXN PR
(starting dose 20/10 mg bid) vs. placebo for chronic
low back pain; n = 83
 OXN PR significantly improved pain intensity scores (P ≤ 0.042) and
overall pain/sleep scores (P = 0.005) vs. placebo
 Changes in BFI and stool consistency were comparable across
treatment groups (most patients were not constipated at baseline)
 Patients and investigators preferred OXN PR to placebo (P ≤ 0.02)
 Outcomes with OXN PR were maintained during a 6-month
open-label extension
Ueberall
et al.62–64
12-week, open-label, blinded endpoint study from
Germany Pain Registry of adults with chronic low back
pain; received (randomized 1:1:1 or physician decision)
morphine, OXN PR, or OXY PR; n = 901 (PROBE)
 In randomized patients (n = 453) OXN PR provided significantly
more responders for a combined measure of treatment continuation,
analgesia, and bowel function (P < 0.001) and a lower risk of
developing OIC vs. OXY PR and morphine (P < 0.001)
 In all patients (n = 901):
 Normal BFI score was maintained in more patients receiving
OXN PR vs. OXY and morphine (P < 0.001)
 OXN PR provided superior analgesia and treatment satisfaction
(both, P < 0.001) and had a better tolerability profile vs. OXY
and morphine
 Greatest gains in HRQoL observed with OXN PR (P < 0.001)
Ueberall &
Mueller-
Schwefe65
Randomly selected 12-week, open-label data from
Germany Pain Registry of adults with chronic low back
pain (neuropathic component) prescribed OXN PR
(n = 128) or tapentadol (n = 133; PROBE 2)
 Noninferior benefit: risk profile of OXN PR vs. tapentadol
 Greater composite analgesic/QoL efficacy (primary endpoint) for
OXN PR (P = 0.014); between group differences increased in favor
of OXN PR with stricter response definitions (P ≤ 0.017)
 OXN PR and tapentadol were similarly well tolerated
Vondrackova
et al.59
12-week RCT of placebo, OXY PR or OXN PR
(10/5 or 20/10 mg bid) in patients with chronic
lower back pain; n = 463 (OXN3401)
 Comparable analgesia with OXY PR and OXN PR (superior to
placebo, P ≤ 0.0003)
 Improved BFI and CSBM scores with OXN PR vs. OXY PR in patients
with baseline moderate-to-severe OIC (BFI ≥ 50)
 No unanticipated AEs with OXN PR
 Efficacy and tolerability of OXN PR was maintained during
12-month open-label extension phase of pooled studies
(OXN3001/OXN3401)60
AE, adverse event; bid, twice daily; BFI, Bowel Function Index; CSBM, complete, spontaneous bowel movement; HRQoL, health-related quality of life; OIC, opioid-induced
constipation; OXN PR, prolonged-release oxycodone/naloxone; OXY, oxycodone; OXY PR, prolonged-release oxycodone; PAC-SYM, Patient Assessment of Constipation Symptoms;
QoL, quality of life; RCT, randomized, controlled trial.
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Low Back Pain. Low back pain is thought to cause
more disability worldwide than any other condition.49
Unfortunately, improved understanding of the etiology
of chronic low back pain has not translated into a
decrease in prevalence or burden.50 Indeed, an estimated
10% of individuals report chronic, impairing low back
pain, of whom 84% seek health care.51 When managing
low back pain, it is recommended that pharmacological
and interventional approaches be considered within a
broader therapeutic framework, which includes physical
and psychosocial strategies.50,52 While consensus on the
role of opioid analgesics to manage low back pain is
lacking,52,53 some treatment guidelines recommend
opioids, sometimes for a limited duration, as an option
for individuals who do not gain adequate relief from
paracetamol or nonsteroidal anti-inflammatory drugs
(NSAIDs).54–57 Clinicians should also establish whether
the source of low back pain is mechanical, neuropathic,
or of mixed origin, as this may influence responsiveness
to opioid therapy.58
While individuals with chronic, moderate-to-severe
low back pain have been included in studies investigat-
ing OXN PR for a broad range of patients with
noncancer pain, we identified 5 studies specifically
investigating OXN PR in this setting (see Table 2).
These include a large-scale (n = 463), 12-week, double-
blind, placebo- and active-controlled RCT.59 OXN PR
(10/5 mg bid or 20/10 mg bid starting dose) was found
to provide comparable analgesia to OXY PR in patients
with moderate-to-severe, chronic low back pain, in
tandem with improved bowel function in the subgroup
of patients with substantial OIC at baseline (BFI score
≥ 50), as demonstrated by BFI and complete, sponta-
neous bowel movement (CSBM) scores.59 The efficacy
and tolerability of OXN PR was maintained during an
open-label, 1-year extension phase of pooled studies.60
Similar findings in this setting were reported in a smaller
scale (n = 83) 4-week, placebo-controlled cross-over
RCT, which showed significant improvements in sleep
and analgesia with OXN PR that were maintained
during a 6-month open-label evaluation.61 While this
study did not demonstrate improvements in BFI scores
with OXN PR vs. placebo during the 4-week random-
ized treatment, most patients were not considered to be
constipated at study baseline (mean [SD] daily bowel
evacuation score of 1.0 [0.5]).
The utility of OXN PR for chronic, moderate-to-
severe low back pain was also investigated in 2
multicenter 12-week observational studies based on
the German Pain Registry (PROBE and PROBE 2; see
Table 2). These studies were designed to reflect routine
clinical practice in Germany and enrolled a broad
Table 3. Summary of Clinical Trials and Observational Studies Investigating OXN PR for Neuropathic Pain
Reference Study Overview Key Outcomes
Gatti et al.76 Retrospective, 2-month observational study
of OXN PR (mean starting dose
15 mg bid, physician determined) in patients
with constipation and chronic
moderate-to-severe pain (~85% with neuropathic
pain; gabapentin/pregabalin
was permitted); n = 1051
 OXN PR reduced pain intensity (P < 0.001) and requirement for rescue
medication from baseline (P < 0.001)
 84% rated PGIC as “very much” or “much” improved
 BFI scores improved from baseline (P < 0.001) despite reduced use of
laxatives (P < 0.001)
Hermanns
et al.74
Observational study of 4-week OXN PR
(dose determined by physician;
10/5 mg bid recommend for
opioid-na€ıve patients); in patients with
neuropathic pain; n = 1488
 OXN PR reduced pain intensity (BPI-SF, P < 0.001) and BFI scores
(Week 4 mean BFI value reflected normal bowel function) vs. prior
analgesic therapy (P < 0.001)
 Pain-related functional impairment (P < 0.001) improved from baseline
 Tolerability was “good/very good” in 89% of patients
Kang et al.77 4-week, single-arm study of OXN PR
(20/10 mg bid starting dose) added to prior
pregabalin or gabapentin in patients
with chemotherapy-induced peripheral
neuropathy (n = 66)
 OXN PR improved pain intensity scores (P < 0.0001)
 OXN PR reduced numb/tingling hands (P = 0.043) and feet (P < 0.0001;
FACT/GOG-Ntx)
 ADRs included dizziness 21% and nausea 10%
Lazzari et al.75 Retrospective, observational, single-center
study of open-label OXN PR (starting
dose ≤ 30/15 mg/day) for 8 weeks in
patients with constipation and
neuropathic pain; n = 200 (all received
concomitant gabapentin/pregabalin)
 OXN PR was associated with improved pain intensity and reduced use
of rescue medication vs. baseline (P < 0.0001)
 BFI improved (P < 0.0001) and laxative use decreased
 For PGIC, 88% reported “much/extremely improved”
 Findings were consistent regardless of age (≥ 65 vs. <65 years) or
etiology of neuropathic pain
ADR, adverse drug reaction; AE, adverse event; BFI, Bowel Function Index; bid, twice daily; BPI-SF, Brief Pain Inventory Short Form; FACT/GOG-Ntx, Functional Assessment of Cancer
Therapy/Gynaecologic Oncology Group/Neurotoxicity; OXN PR, prolonged-release oxycodone/naloxone; PGIC, Patients’ Global Impression of Change; QoL, quality of life; RCT,
randomized, controlled trial.
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spectrum of patients who required opioid analgesics to
manage their pain. While these studies were of open-
label treatment, analysis of study endpoints was
blinded.62–65 The PROBE study included 453 patients
randomized to OXN PR, OXY PR, or morphine and
448 patients with opioid medication allocated based on
physician decision. In the randomized cohort, signifi-
cantly more patients receiving OXN PRwere responders
Table 4. Summary of Clinical Trials and Observational Studies Investigating OXN PR for Pain Associated with
Osteoarthritis and Other Musculoskeletal Disorders
Reference Study Overview Key Outcomes
Blagden
et al.81
Pooled analysis of 12-month extension
phases of open-label OXN PR
(≤ 120/60 mg/day) following two 12-week,
double-blind RCTs of OXN PR vs.
OXY PR in patients with moderate-to-severe
chronic pain and OIC at baseline
(OXN3001/OXN3006); n = 474
(~87% with musculoskeletal pain)
 OXN PR maintained analgesic efficacy and bowel function (BFI scores)
observed in prior 12-week RCT for up to 12 months
 Improvement in BFI scores was most marked in patients who received OXY
PR during prior double-blind treatment
 No new safety issues were observed with long-term OXN PR
Hesselbarth
et al.83, 84
Prospective, observational 4 to 6 week study
of OXN PR (dosed according
to pain severity) vs. other
opioids; n = 588 (~92% with
moderate-to-severe musculoskeletal pain)
 Greater reductions in baseline pain intensity with OXN PR vs. other opioids
(P < 0.0001)
 Improvements BFI score were observed with OXN PR (P < 0.0001) but not
other opioids (patients in “other opioid” group did not have constipation
at baseline)
 HRQoL gains (BPI-SF composite pain interference and EQ-5D scores) were
more pronounced with OXN PR vs. other opioids
 More patients rated the effectiveness (73% vs. 55%) and tolerability
(84% vs. 69%) of OXN PR as “very good/good” vs. other opioids
 Similar outcomes to the total population were observed in the OXN PR
40/20 mg/day cohort (n = 48) and in an opioid-na€ıve subgroup (n = 148)
Lowenstein
et al.72
Double-blind, 12-week RCT of OXN
PR (titrated to ≤ 80/40 mg/day)
vs. OXY PR in patients with
moderate-to-severe chronic pain and
OIC; n = 278 (back pain 61%,
OA ~29%, osteoporosis ~10%; OXN3006)
 Improvements in BFI scores observed with OXN PR vs. OXY PR after 1 week
were maintained to week 12 (P < 0.0001)
 More CSBM and lower laxative use (P = 0.0009) with OXN PR
 Comparable analgesic efficacy with OXN PR and OXY PR
 No unanticipated safety signals with OXN PR
Lowenstein
et al.80
Pooled analysis of two 12-week,
double-blind RCTs of OXN PR vs.
OXY PR in patients with moderate-to-severe
chronic pain and
OIC (OXN3001/OXN3006); n = 587
(86% with musculoskeletal pain)
 Noninferior analgesia with OXN PR vs. OXY PR
 Improved bowel function with OXN PR, including lower BFI scores and less
laxative use (P < 0.0001)
 Comparable general health (SF-36) and patient satisfaction (TSQM) with
OXN PR vs. OXY PR
 No unanticipated AEs with OXN PR
Rosa et al.82 Randomized, 4-week, single-center
study of OXN PR vs. other
opioid analgesics (OXY, transdermal fentanyl,
hydromorphone) in patients with
chronic osteoarticular
pain; n = 60
 OXN PR was associated with shorter duration to titrate to effective analgesic
dose (15 vs. 17 days), lower effective dose (72 vs. 80 mg), and longer duration
of stable dose (77 vs. 58 days) vs. other opioids
 OXN PR was also associated with improved BFI scores, which was not
observed in the “other opioids” group
Schutter
et al.85
Prospective, observational
4-week study of OXN PR
(dose determined by treating physician)
in patients with
severe chronic pain; n = 7836
(86% musculoskeletal pain)
 OXN PR reduced strongest pain (P < 0.001) and increased the proportion of
patients without pain in the prior 24 hours (P < 0.001)
 BFI scores improved in all patients (P < 0.001); improved BFI was most marked
in opioid-pretreated patients (opioid-na€ıve patients were not constipated
at baseline)
 Serious ADRs were reported by 2.3%
 Efficacy and tolerability were considered “good” or “very good” by 84%
and 87%, respectively
Simpson
et al.73
Double blind, 12-week RCT of
OXN PR (mean dose 33 mg/day)
vs. OXY PR in patients with
moderate-to-severe chronic pain
and OIC; n = 322 (~72% with OA; OXN3001)
 Improved BFI scores with OXN PR vs. OXY PR were observed after 1 week
and maintained (P < 0.0001)
 More CSBM and lower laxative use with OXN PR (P < 0.0001)
 Analgesic efficacy of OXN PR and OXY PR was comparable
 No unanticipated AEs with OXN PR
 Efficacy and tolerability was maintained during 12-month open-label
extension phase of pooled studies (OXN3001/OXN3401)60
ADR, adverse drug reaction; AE, adverse event; BFI, Bowel Function Index; BPI-SF, Brief Pain Inventory Short Form; CSBM, complete, spontaneous bowel movement; HRQoL, health-
related quality of life; OA, osteoarthritis; OIC, opioid-induced constipation; OXN PR, prolonged-release oxycodone/naloxone; OXY, oxycodone; OXY PR, prolonged-release
oxycodone; RCT, randomized, controlled trial; SF-36, Short Form-36; TSQM, Treatment Satisfaction Questionnaire for Medicine.
OXN PR for Pain and Opioid-Induced Constipation  7
Table 5. Clinical Studies Investigating OXN PR for Parkinson’s Disease-Related Pain, Severe Bladder Pain, Pain in Elderly
Patients, and in Laxative-Refractory Patients with Pain
Neurologic Disorders Study Overview Key Outcomes
Parkinson’s disease–related pain
Madeo et al.89 8-week single-center, uncontrolled study
(OXN PR 5/2.5 mg bid) in Parkinson’s
disease–related pain; n = 16
 OXN PR provided analgesia (P < 0.05)
 No adjustments to dopaminergic therapy were required
 No detrimental effect on BFI scores or sleep
 2 patients (12.5%) discontinued due to AEs
Trenkwalder et al.88 Placebo-controlled, 16-week RCT
(OXN PR 5/2.5 mg bid starting dose)
followed by 4-week extension phase of
open-label OXN PR in severe Parkinson’s
disease–related pain; n = 202 (OXN3502)
 Improvements in pain scores at weeks 4 to 12 (P ≤ 0.021;
week 16 primary endpoint was not met) and in the per
protocol population at week 16 (P = 0.010) with OXN
PR vs. placebo
 Improvements in severe musculoskeletal pain and nocturnal
pain at week 16 with OXN PR vs. placebo (P ≤ 0.023)
 There were more responders for CGI-I (P = 0.02) and
reduction of baseline pain (P = 0.02) with OXN PR vs. placebo
 No worsening of other nonmotor symptoms
 Treatment-related AEs 57% in both groups and no
unanticipated adverse effects
Severe bladder pain syndrome
Goebell et al.99,100 Pilot RCT of OXN PR (≤ 20/10 mg bid) or
placebo for 8 weeks followed by open-label
OXN PR for 4 weeks in women with severe
bladder pain syndrome; n = 60
 Greater improvements in pain scores with OXN PR vs.
placebo at week 8, and further decreases during open-label
OXN PR
 Lower use of rescue ibuprofen with OXN PR vs. placebo
 Lower impact of urinary and pain symptoms (ICSI, ICPI) with
OXN PR vs. placebo (P ≤ 0.019)
 Fewer AEs with OXN PR vs. placebo
Elderly patients
Guerriero et al.107,108 Open-label prospective study of OXN PR
(starting dose 10/5 mg/day) in opioid-na€ıve
patients ≥ 70 years of age with noncancer
pain for 4 weeks, followed by 52-week
extension phase; = 53
 OXN PR improved pain (P < 0.0001) and reduced the need
for rescue paracetamol (P < 0.0001) at week 4 vs. baseline
 No decline in cognitive (MMSE) or bowel (BFI) functions
were reported at week 4 or week 52
 ≥ 30% reduction in baseline pain intensity without worsening
bowel function was achieved at week 4 and week 52 by
78% and 96%, respectively (P < 0.0001)
 OXN PR improved daily functioning at week 4 and week 52
(Barthel Index, P ≤ 0.01)
 OXN PR was generally well tolerated long-term
Petro et al.109 Prospective, open-label 45-day study of OXN
PR (5/2.5 mg bid starting dose) in opioid-na€ıve
patients > 65 years of age with musculoskeletal
pain (94%) and cognitive impairment; n = 53
 OXN PR improved mean pain intensity (P < 0.0001) and daily
functioning (Barthel Index, P < 0.0001)
 Improvements in neuropsychiatric symptoms
(Neuropsychiatric Inventory) were also reported (P < 0.0001)
 OXN PR was well tolerated and did not worsen bowel
function
Laxative-refractory patients
Jones & Tripathi111 Single-center, observational study of OXN PR
(mean starting dose 10.6/5.3 mg/day) in patients
with chronic pain (54% low back pain) and OIC
despite laxative use (31% ≥ 2 classes of laxatives);
n = 26
 BFI scores improved from baseline at week 4 (P < 0.001),
week 8 (P < 0.05), and week 12 (P < 0.001)
 Reduction in pain scores were observed from baseline to
week 12 (P < 0.05)
 83.3% indicated OXN PR as improvement on their prior
medication
 AEs reported by 23%
Koopmans et al.110 Pooled analysis of OXN PR (20/10 to 120/60 mg/day)
for 4 weeks or 12 weeks in patients with
cancer-related or noncancer pain and OIC refractory
to ≥ 2 classes of laxatives (studies OXN2001,
OXN9001); n = 75
 OXN PR improved BFI scores: mean reduction 21.2 points
(P ≤ 0.0002)
 BFI was within normal range (≤ 28.8) in 43% of patients
by day 15
 36% of patients stopped using laxatives (P < 0.001)
 Pain scores remained stable and no unanticipated AEs were
reported
Mehta et al.113 Single-center, observational study of OXN PR (starting
dose 10/5 mg/day) for 12 weeks in patients with
noncancer pain and OIC unable to tolerate/not
responded to laxatives; n = 28
 Mean baseline BFI score (79.3) reduced to within normal
range (≤ 28.8) by week 1 (P < 0.001) and was maintained
to week 12 (P = 0.004)
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for the primary endpoint comprising lack of premature
treatment discontinuation, BFI worsening ≤ 50% from
baseline, and ≥ 50% improvement from baseline in
pain-related measures.63 In the overall population
(n = 901), more patients receiving OXN PR also
reported ≥ 50% improvement in pain intensity, func-
tional disability, and QoL measures and more main-
tained BFI scores within normal range compared with
patients receiving morphine or OXY PR.62–64 These
findings are supported by PREFER, a 3-week, open-label
study investigating patient preference for opioid ther-
apy. Of 169 patients (62% had low back pain), OXN
PR improved QoL measures, with most marked gains in
individuals with OIC who were previously treated with
WHO step II analgesics; greater patient preference for
OXN PR compared with prior opioid analgesic therapy
was also reported.66
PROBE 2, the second open-label, blinded endpoint,
12-week observational study, investigated the efficacy
and tolerability of OXN PR and tapentadol, a l-opioid
receptor agonist and selective noradrenaline reuptake
inhibitor, in patients with low back pain with a
neuropathic component.65 Using a composite endpoint
that captured improvement in pain, pain-related dis-
ability, and QoL, the benefit:risk profile of OXN PRwas
shown to be noninferior to tapentadol, and to be
superior to tapentadol when more stringent response
criteria were applied. The safety/tolerability profiles of
OXN PR and tapentadol were reported to be broadly
comparable.65 OXN PR (starting dose 10/5 mg bid) was
also compared with tapentadol in a 12-week RCT of
258 opioid-na€ıve patients with chronic low back pain
that included a neuropathic component. Noninferiority
of the treatments in terms of analgesia and constipation
was demonstrated.67,68 This study suggested greater
improvements in neuropathic pain-related symptoms
and health-related QoL and a favorable safety profile
with tapentadol vs. OXN PR.67,68 This finding is in
contrast to PROBE 2 and underlines the need for further
head-to-head trials and to consider the individual safety
profiles of therapies and optimal dosing strategies to
personalize analgesic therapy.
Neuropathic Pain. Neuropathic pain, or pain arising as
a direct consequence of a lesion or disease affecting the
somatosensory system, can be very disabling and has
numerous causes and manifestations.69 For example,
affected patients may include those with neuropathy due
to diabetes, cancer patients receiving chemotherapy,
patients with nerve lesions following trauma or surgery,
and patients with central nervous system lesions such as
stroke or spinal cord injury.70 Unfortunately, more than
two-thirds of patients with neuropathic pain are
reported to obtain insufficient pain relief.69 Treatment
recommendations from the Special Interest Group on
Neuropathic Pain (NeuPSIG) support the use of OXY
and morphine as third-line therapy for individuals with
inadequate pain relief using other agents, including
anticonvulsants, tricyclic antidepressants, serotonin
noradrenaline reuptake inhibitors, or lidocaine
patches.71
While several RCTs of OXN PR have included
some patients with moderate-to-severe neuropathic
pain,72,73 the effectiveness and tolerability of OXN
PR in this setting was specifically investigated in 4
studies identified in our literature search (see Table 3).
Two large-scale observational studies included a total
of 1,688 patients with neuropathic pain, receiving
OXN PR at mean starting doses of 24.4 mg/day and
16 mg/day, respectively (concomitant gabapentin/
pregabalin was permitted).74,75 In these “real-life”
settings, OXN PR provided clinically relevant
improvements in pain, functional impairment, and
BFI scores compared with prior therapy, and was
Table 5. (Continued)
Neurologic Disorders Study Overview Key Outcomes
 Baseline PAC-QOL scores were improved from week 1 to
week 12 (P ≤ 0.005)
Poelaert et al.112 Observational study of OXN PR (median dose
20/10 mg/day) for 12 weeks in patients with
noncancer pain (91%) and OIC refractory
to ≥ 2 classes of laxatives; n = 68
 OXN PR was associated with improvements in pain
(P < 0.001) and BFI (mean reduction 48.5 points,
P < 0.001) vs. prior OXY PR
 Improvements in EQ-5D QoL scores were reported (P < 0.001)
 Laxative use reduced from baseline (96% vs. 39%, P < 0.0001)
 AEs reported by 2.9%
AE, adverse event; bid, twice daily; BFI, Bowel Function Index; CGI-I, Clinical Global Impression-Improvement; ICPI, O’Leary-Sant Intestitial Cystitis Problem Index; ICSI, O’Leary-Sant
Interstitial Cystitis Symptom Index; MMSE, Mini-Mental State Examination; OIC, opioid-induced constipation; OXN PR, prolonged-release oxycodone/naloxone; OXY PR, prolonged-
release oxycodone; PAC-QOL, Patient Assessment of Constipation Quality of Life; QoL, quality of life; RCT, randomized, controlled trial.
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reported to be well tolerated.74,75 These findings are
supported by a third large-scale observational study of
OXN PR (mean starting dose 15/7.5 mg/day; 19%
received concomitant anticonvulsants) in 1,051
patients with constipation (37% had received prior
opioid analgesia), of whom approximately 85%
had chronic, moderate-to-severe neuropathic pain.76
Furthermore, in a 4-week, single-arm study of 66
patients with chemotherapy-induced peripheral neu-
ropathy inadequately controlled by pregabalin or
gabapentin, additional OXN PR (20/10 mg/day start-
ing dose) provided improved pain relief and neuro-
pathic symptom control (reduced numbness/tingling of
hands and feet).77
Table 6. Clinical Studies Investigating OXN PR for Postsurgical Pain
Reference Study Overview Key Outcomes
Comelon
et al.91
RCT of OXY PR vs. OXN PR (10/5 mg bid) for
3 days after laparoscopic hysterectomy; n = 85
 Comparable bowel function for OXY PR and OXN PR
 Comparable analgesia and adverse effect profile for both groups
 Few patients were dissatisfied with their pain medication
(OXY PR 11%, OXN PR 5%)
Creamer
et al.97
Open-label, single-center feasibility study of
OXY PR vs. OXN PR (10/5 mg prior to anesthesia
then 5/2.5 to 20/10 mg bid) until discharge from
hospital for laparoscopic colorectal surgery; n = 50
 Return to gut function by day 3 may be similar with OXY PR vs. OXN
PR (65% vs. 48%, P > 0.05)
 OXN PR vs. OXY PR was associated with a shorter time to first bowel
movement (87 vs. 111 hours, P = 0.031)
 Total opioid consumption may be similar with OXY PR vs. OXN PR
 (78 vs. 94 mg, P > 0.05)
Kampe
et al.92
Single-center, retrospective study
OXY PR vs. OXN PR (20/10 mg every 6 hours)
administered with metamizole
following thoracic surgery or thoracoscopy; n = 788
 OXN PR provided less effective analgesia than OXY PR on day 2
(P ≤ 0.01) and comparable analgesia on days 5 and 6
 More patients receiving OXN PR vs. OXY PR received oral opioids
following discharge from hospital (P ≤ 0.004)
Kokki
et al.98
RCT (single-blind) of OXY PR vs. OXN (10/5 mg bid)
for 7 days following spinal
surgery; n = 180 (opioid-na€ıve and
on-opioid subgroups)
 Constipation was common at baseline: 29% and 48% of opioid-na€ıve
and on-opioid patients, respectively
 Opioid-na€ıve: day 7, constipation similar with OXN PR (57%) vs.
OXN PR (58%) but was less prevalent at day 21 (20% vs. 7%)
 On-opioid: constipation similar with OXN PR vs. OXY PR on day
7 (64% vs. 64%) and day 21 (16% vs. 17%)
 Use of laxatives was lower with OXN PR vs. OXY PR in opioid-na€ıve
and on-opioid subgroups
 Analgesia was similarly effective for OXN PR vs. OXY PR in
opioid-na€ıve and on-opioid subgroups
Kuusniemi
et al.93
3 studies of OXN PR in postorthopedic surgery settings:
 IPOP: RCT of OXN PR (20/10 mg bid
or 10/5 mg bid) vs. OXY PR; n = 137 (OXN4505)
 NIS: open-label, prospective study of OXN
PR (dose determined by investigator) vs.
other opioids; n = 80 (OXN9503)
 QIP: open-label, prospective follow-up study
of OXN PR (dose determined by investigator);
n = 44
 IPOP: similar analgesic efficacies of OXN PR and OXY PR
 NIS: OXN PR was associated with less restriction to carry out physiotherapy,
lower use of laxatives (21% vs. 32%), and better tolerability vs. other opioids
 QIP: OXN PR was associated with improved bowel function (P ≤ 0.04) and
ability to pass urine (P = 0.03) vs. baseline
 No safety concerns were raised in any study
Oppermann
et al.94
Prospective, noninterventional study of
OXN PR (10/5 mg bid starting dose) vs.
other opioids following total knee
replacement; n = 80
 Similar analgesia with OXN PR vs. other opioids
 OXN PR was associated with numerically better bowel function
(mean BFI scores were within normal range) and better early
functional outcomes (modified Larson score) vs. other opioids
(P = 0.018)
 OXN PR was generally better tolerated: ADRs 23% vs. 38%
Ruetzler
et al.95
Randomized open-label, single-center
study of OXN PR vs. patient-controlled IV
morphine (equivalent starting doses)
following cardiac surgery; n = 51
 Similar analgesia with OXN PR and morphine
 Total opioid dose was lower for OXN PR vs. morphine
(34 vs. 69 mg, P < 0.001)
 OXN PR was generally better tolerated than morphine
Scardino
et al.96
Retrospective single-center study of
OXN PR (10/5 mg bid starting dose) with oral
ketoprofen for 4 days after total
hip replacement; n = 282
 Pain was well controlled during rest and movement (no patients
had severe breakthrough pain)
 72% were “very satisfied” with their pain therapy
 No patient reported severe pain or required IV morphine rescue
ADR, adverse drug reaction; BFI, Bowel Function Index; bid, twice daily; IPOP, immediate postoperative period; NIS, noninterventional study; OXN PR, prolonged-release oxycodone/
naloxone; OXY PR, prolonged-release oxycodone; QIP, quality improvement program; RCT, randomized, controlled trial.
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Pain Due to Osteoarthritis and Other Musculoskeletal
Disorders. Osteoarthritis (OA) affects an estimated 27
million and 8.5 million adults in the United States and
United Kingdom, respectively.78 The prevalence of OA
increases with age, affecting approximately one-third of
individuals ≥ 65 years of age.78 Pain is the hallmark
symptom of OA and arises due to intra-articular and
extra-articular factors.78 Patients with OA are treated
with a combination of nonpharmacologic and pharma-
cologic modalities, with opioid analgesics recommended
for those who do not respond to acetaminophen, if
NSAIDs and cyclooxygenase (COX)-2 inhibitors are
contraindicated, and for patients with contraindications
or unwilling to undergo total joint arthroplasty having
failed medical therapy.58,79
Most studies identified in our literature search that
investigated the impact of OXN PR on OA also included
patients with other types of moderate-to-severe pain,
including musculoskeletal conditions such as osteoporo-
sis (see Table 4). These include two 12-week, double-
blindRCTs inwhichpatientswithOIC receivedOXNPR
at daily doses of up to 80/40 mg (1 study permitted up-
titration to 120/60 mg/day for patients regularly taking
> 2 doses of rescue medication).72,73,80 In both studies,
OXN PR was associated with comparable analgesia to
OXY PR and better bowel function, including clinically
relevant improvements in BFI score, increased number of
CSBMs, and reduced laxative intake.72,73,80 Pooled data
from 12-month extension phases of both RCT studies, in
which patients completing double-blind treatment with
OXN PR or OXY PR received open-label OXN PR,
demonstrated that pain control and bowel function with
OXN PR was maintained long term, and no new safety
issues were detected.81 Similar findings were also
reported in a 4-week, open-label randomized trial of 60
patients with osteoarticular pain. In this study, OXN PR
provided a lower andmore stable effective analgesic dose
compared with other opioid analgesics (oxycodone,
hydromorphone, and transdermal fentanyl) as well as
improved BFI scores.82
The utility of OXN PR to treat moderate-to-severe
musculoskeletal pain during routine clinical practice
was investigated in 2 large-scale observational studies
(see Table 4). These studies included 8,424 patients in
total (> 86% had musculoskeletal pain, with causes of
pain specified in 1 study only, which included degener-
ative spinal diseases, severe OA/arthritis, and osteporo-
sis).83–85 Both studies found OXN PR provided more
effective pain relief than prior analgesics, including
other opioids, and had a positive impact on BFI scores.
OXN PR was also considered “good/very good” in
terms of efficacy and tolerability by ≥ 73% of
patients.83–85 Furthermore, 1 study reported that the
therapeutic benefits of OXN PR in this setting were
more pronounced compared with other opioids.83,84
Parkinson’s Disease–Related Pain. In addition to the
cardinal motor symptoms of Parkinson’s disease, pain is
a common nonmotor symptom that affects two-thirds of
patients with this disease.86 Parkinson’s disease–related
pain is a complex disorder and has a variety of
manifestations, including musculoskeletal, visceral, noc-
turnal, orofacial, limb, and abdominal pain.87 Low-dose
OXN PR (5/2.5 mg bid starting dose) was investigated
in 2 studies of Parkinson’s disease–related pain (see
Table 5). A phase II study of 202 patients with severe
Parkinson’s disease–related pain found that while the
numerical reduction in 24-hour pain at week 16 was not
statistically significant with OXN PR vs. placebo in the
full analysis population, OXN PR was associated with
significant improvements in average 24-hour pain at
weeks 4, 8, and 12, and in the per protocol population at
week 16.88 Patients with severe musculoskeletal or
nocturnal types of Parkinson’s disease–related pain at
baseline who received OXN PR reported significant
improvements at week 16 compared with placebo.88
Furthermore, OXN PR was not associated with wors-
ening of other Parkinson’s disease nonmotor symptoms,
including mood and perceptual disorders, and there
were no unanticipated adverse effects.88 The findings
from this study are supported by an 8-week observa-
tional study of OXN PR, which also reported clinically
significant reductions in pain and no worsening of bowel
function in 16 patients with moderate-to-severe Parkin-
son’s disease–related pain.89
Postsurgical Pain. Guidelines recommend a tailored
approach for the management of postoperative pain,
and short-acting oral opioids are generally preferred
over long-acting oral opioids for the immediate postop-
erative period, due in part to dose titration require-
ments.90 Our literature search identified 8 studies
investigating short-term administration of OXN PR to
manage pain following surgery, including RCTs,
open-label studies, and retrospective studies (see
Table 6).91–98 Together, the finding suggested broadly
comparable analgesia with OXN PR vs. OXY PR,
morphine, or other opioid analgesics, and some but not
all studies also documented additional improvements in
bowel function and early functional outcomes with
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OXN PR.91–98 High patient satisfaction (72% “very
satisfied”) with OXN PR plus oral ketoprofen was
reported in a study of patients following hip replace-
ment.96 One study conducted in an orthopedic surgery
setting investigated bladder function and reported less
difficulty in passing urine with OXN PR vs. OXY PR.93
Bladder Pain. A pilot RCT of 60 women with severe
pain due to bladder pain syndrome reported improve-
ment in pain scores, lower use of rescue medication, and
lower impact of urinary and pain symptoms with OXN
PR at doses of up to 20/10 mg bid compared with
placebo (see Table 5).99,100
Elderly Patients with Chronic Moderate-to-Severe
Pain. Chronic moderate-to-severe pain is particularly
prevalent in elderly individuals, due in part to age-
related increases in the incidences of cancer and
degenerative diseases such as OA. Given the demo-
graphic imperative of an aging population, addressing
chronic pain in older individuals is a growing prior-
ity.101 However, this can be complicated by age-related
factors such as comorbidities, concomitant medica-
tions, physiological changes affecting drug bioavail-
ability, and cognitive decline.102 Evidence that NSAIDs
and COX-2 inhibitors can lead to life-threatening
adverse effects in older patients with gastrointestinal
or cardiovascular disease has shifted attention to opioid
analgesics.103 While opioids are recommended for
selected elderly patients with chronic, severe, cancer-
related, and noncancer pain, careful management of
therapy is cautioned and it is recommended that the
safety profile of different opioids be considered when
selecting opioids for this patient group.103,104 It is
widely recognized that constipation is more common in
elderly patients, which may be due to reduced mobility,
dietary factors, medical conditions, and/or concomitant
medications.105 Consequently, this population may be
particularly vulnerable to OIC. Indeed, OIC was
reported in 86% of older patients (mean age 61 years)
receiving opioid analgesia in a large-scale observational
study.106
While several RCTs of OXN have included a number
of older patients,41,72,88 our literature search also
identified studies in which OXN PR (starting dose
10/5 mg/day) was specifically investigated in elderly
individuals (see Table 5). In an open-label, prospective
study of 53 opioid-na€ıve older patients (mean age
81 years) with chronic noncancer pain, OXN PR for
up to 1 year significantly improved pain and
functioning, and was generally well tolerated with no
negative effects on cognitive functioning or BFI
scores.107,108 A second open-label, prospective study of
53 elderly patients with cognitive impairment and
moderate-to-severe musculoskeletal pain also reported
improved analgesia and daily functioning with OXN PR
without worsening bowel function; interestingly, a
significant improvement in dementia-associated symp-
toms was also observed.109
Laxative-Refractory Patients with ChronicModerate-to-
Severe Pain. Laxatives are effective for many (but not
all) patients with idiopathic constipation, and the same
holds true for patients with OIC.9 Potential reasons for
failure of laxatives include poor tolerance (including
unpalatable taste and adverse effects such as bloating),
unpredictable onset of action, and lack of efficacy.
Indeed, some patients have OIC that is particularly
difficult to treat, including individuals who experience
no symptomatic relief despite taking several different
types of laxatives. Small-scale studies and a retrospective
analysis were identified in our literature search indicat-
ing that OXN PR may be an effective treatment option
for these patients.110–113
A pooled analysis of RCTs investigating OXN PR vs.
OXY PR for chronic moderate-to-severe pain included a
subgroup of 75 patients with OIC who had not been
treated satisfactorily with at least 2 classes of laxa-
tives.110 These patients experienced significant improve-
ments in BFI scores from baseline, with 43% of
individuals having a BFI score within the normal range
by day 15.110 Similar findings were reported in a small
(n = 26), 12-week, single-center study of OXN PR in
patients with OIC despite laxative therapy in which
83% of patients reported OXN PR was better than their
previous opioid analgesia regimen.111 Two 12-week
observational studies of patients with laxative-
refractory OIC also reported clinically relevant improve-
ments in pain, bowel function, and QoL compared with
prior treatments.112,113
Cost-Effectiveness Studies of OXN PR for Moderate-to-
Severe Pain
Cost-utility studies were identified in our literature
search, which together demonstrate that OXN PR is a
cost-effective treatment compared with OXY PR for
patients with moderate-to-severe pain and OIC. These
studies included 3 analyses based on RCT data,
performed in the United Kingdom, Canada, and Italy,
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indicating that while analgesic costs are higher for OXN
PR than OXY PR, drug cost is offset by lower use of
laxatives, other healthcare resources, and greater QoL
gains.114–116 Indeed, the incremental cost-effectiveness
ratio of OXN PR per quality-adjusted life-year gain was
estimated to be £5,841, €475, and $2,178 to $7,732
CDN, and reported to be well below accepted cost-
effectiveness thresholds.114–116 An 8-week question-
naire-based observational study conducted in Sweden
also indicated that switching from OXY PR and
laxatives to OXN PR was associated with QoL gains
and reduced need for healthcare visits, fewer hospital-
izations due to pain or constipation, and reduced
laxative use, which together translated into direct cost
savings.117 Tapentadol extended-release (ER) was
reported to be slightly more cost-effective than OXN
PR for treating OIC in 1 economic evaluation based on a
meta-analysis of 3 RCTs, due to lower incidence of
adverse events and fewer discontinuations.116
DISCUSSION
Extensive data from clinical trials and real-world studies
demonstrate that OXN PR provides effective analgesia
for moderate-to-severe cancer-related pain and non-
cancer pain types such as low back pain, neuropathic
pain, musculoskeletal pain, Parkinson’s disease–related
pain, and postsurgical pain.41,59,73,76,85,88,93 Further-
more, limited studies conducted specifically in elderly
patients indicate that OXN PR is effective in this setting
with no unanticipated safety concerns.108 Given the
substantial impact of OIC on patients’ QoL and the
economic burden of this condition, which has been
attributed to increased healthcare utilization and
reduced work productivity,118,119 it is important to note
that most studies of OXN PR demonstrated substantial
improvements in bowel function in patients with OIC.
This includes clinically significant reductions in BFI
scores in patients with OIC refractory to at least 2
different types of laxatives110 and BFI scores approach-
ing nonconstipated values in several studies of patients
with OIC at baseline.44,81 The observation of effective
analgesia in tandem with cognitive improvements in a
small open-label study of patients with musculoskeletal
pain and cognitive impairment was interesting; how-
ever, further RCTs are required to validate this find-
ing.109 In addition, while much of the published data on
OXN PR across indications and treatment settings we
identified were from double-blind RCTs or large-scale
observational studies designed to reflect real-world
practice,41,63,80,85 the majority of this research was
initiated by the pharmaceutical company that manufac-
tures OXN PR.
All patients initiating opioid analgesia should be
educated about OIBD, including OIC. To our knowl-
edge, there are no RCTs suggesting that 1 particular
laxative is most effective for managing OIC symptoms.
Indeed, systematic reviews investigating laxatives in
constipated palliative care patients, the majority of
whom are receiving opioid analgesia, conclude that
evidence for a role of laxatives in this setting is
limited.120,121 While laxatives are widely used as first-
line therapy for OIC, several recent treatment guidelines
recommend that opioid-antagonist-based therapies be
considered either when initiating opioid therapy or for
patients with OIC who fail to respond to laxatives, and
provide a strong recommendation that OXN PR is more
effective than oxycodone at avoiding OIC.7,11,13 This is
supported by several studies concluding that OXN PR is
a cost-effective treatment compared with OXY PR, due
to lower use of laxatives and healthcare resources, as
well as QoL gains.114–116 Based on available evidence,
OXN PR represents a rationale treatment option for
appropriately selected patients with moderate-to-severe
pain, either to manage or avoid OIC. However, it should
be remembered that patients receiving OXN PR may
still require laxatives to address their constipation,
which can be due to causes in addition to opioid therapy.
The fixed-dose combination formulation of OXN PR
is associated with patient convenience and potential
improved compliance compared with separate tablets of
OXY PR and naloxone. However, disadvantages of a
fixed dose include a lack of flexibility regarding the
opioid:naloxone ratio, which may be suboptimal for
some patients, as well as increased tablet cost compared
with opioid plus laxatives. Further, while the available
OXN PR 5/2.5 mg, 10/5 mg, 20/10 mg, and 40/20 mg
tablets provide flexibility for dose titration, not all doses
can be achieved. Initial studies of OXN PR were
conducted across a limited dose range (up to 20/10 mg
bid).30,59 Based on growing experience with OXN PR
and to meet the analgesic needs of a broader range of
patients, this dose range was expanded in subsequent
studies. OXN PR at doses of 5/2.5 mg bid is reported to
provide effective analgesia in some settings, for example,
in some elderly patients with noncancer pain and in
individuals with severe types of Parkinson’s disease–
related pain.88,107–109 However, many patients require
higher doses of OXN PR to obtain sufficient pain relief.
While the usual starting dose of OXN PR in opioid-
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na€ıve patients is 10/5 mg bid, OXN PR is approved at
daily doses of up to 160/80 mg for patients previously
maintained on a stable daily dose who require increased
analgesia.27 Indeed, an RCT of OXN PR in patients
with cancer-related and noncancer pain who required
high doses to manage their pain demonstrated improved
bowel function compared with OXY PR and effective
analgesia with absence of an analgesic ceiling effect
across the clinically relevant dose range investigated (up
to 160/80 mg/day).42 There are also case reports of
OXN PR 180/90 mg/day reducing pain scores and
improving QoL and OIC symptoms in patients with
refractory pain.122
While OXN PR has considerable utility for moderate-
to-severe pain while addressing OIC, as with other stong
opioid analgesics it can be associated with significant
adverse effects, which can include sedation and dizziness
and gastrointestinal events.27,123 As such, caution must
be exercised when OXN PR is given to elderly or infirm
patients or individuals with renal or hepatic impairment
(OXN PR in contraindicated in patients with moderate-
to-severe hepatic impairment).27 Risk for potentially
fatal respiratory depression is a particular concern when
opioids are taken in excess.27,123 Due in part to concerns
about overdose, addiction, and misuse of opioid anal-
gesics, undertreatment of chronic moderate-to-severe
pain is common.7,124,125 When opioid analgesics are
used appropriately, the risk for addiction is generally
considered to be low.126 This is supported by studies
indicating that adaptation of specific spinal and
supraspinal molecular systems associated with chronic
pain can decrease the reward effects of exogenous
opioids, an effect that may be influenced by polymor-
phisms in opioid receptor and neuropeptide genes.127
However, it is widely recognized that abuse and diver-
sion of opioid analgesics is a significant public health
challenge, despite screening tools designed to reduce the
risk for misuse.128 Abusers may manipulate opioid
formulations to obtain faster absorption and a state of
euphoria, for example, by nasal insufflation or intra-
venous administration of dissolved tablets. OXN PR has
abuse-deterrent properties because increased systemic
exposure to naloxone antagonizes the effects of OXY,
which discourages tampering. Soluble OXN was shown
to have significantly less drug-liking and rewarding
effects in a randomized, placebo-controlled study of
recreational opioid users, and reduced pharmacody-
namic responses, drug-liking, and other measures of
abuse potential have also been reported for OXN PR
compared with OXY when chewed or administered
intranasally.129–131 Indeed, a fall in the rate of opioid-
related deaths in recent years has been attributed in part
to the introduction of abuse-deterrant formulations of
opioid analgesics.132 Despite the availability of abuse-
deterrant formulations, clinicians continue to play a
central role in the careful selection and comprehensive
monitoring of patients receiving opioid analgesics, and
must be adequately trained to look for signs of abuse
and misuse.133 Guidance for European healthcare pro-
fessionals in the prevention, detection, and management
of opioid analgesic dependence has recently been
published.134 Additional, large-scale studies are also
required to provide further insight on the impact of
OXN PR on deterring opioid abuse in Europe.
In summary, data from a wide variety of clinical trials
and observational studies confirm that for selected
patients, OXN PR can provide effective analgesia in a
wide variety of moderate-to-severe pain settings. Treat-
ment should be administered using a flexible dosing
strategy that is tailored to the needs of individual patients.
Consistent reports of improved bowel function associated
with OXN PR in patients with OIC also underscores the
rationale for combining the centrally acting opioid anal-
gesic (OXY) and the locally acting antagonist (naloxone),
which has demonstrated antagonism throughout the gut,
to address the unique etiology of OIC.
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